Prevalence of Diabetes-related Autoantibodies Among Individuals With Type 2 Diabetes From Primary Care and Endocrinology Community Practice Settings
Authors' conclusion
The prevalence of diabetes-related autoantibodies in individuals with type 2 diabetes in a U.S. community-based care setting, most of whom did not display LADA phenotype characteristics, was notable and similar regardless of management by endocrinology or PCP practices. Although further studies are needed to assess the clinical implications of these findings, it is possible that proactive awareness of autoantibody status in individuals with type 2 diabetes could provide additional context to help guide treatment decisions.
Study context
- Population
- Adults with T2D without a history of LADA, US community-based endocrinology or primary care practices199 with full panel
- Participants
- 202 adults
- Exposure
- Endocrinology vs PCP management
- Endocrinologyn = 102
- Primary care providers (PCPs)n = 100reference
- Outcome
- Prevalence of diabetes-related autoantibodies (GAD-65, anti-islet cell, insulinoma-associated-2, zinc transporter 8, anti-insulin)
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
- Overall prevalence of ≥1 autoantibody
- 13.6%
Observational data: associations, not effects.
Further findings
GAD-65 positivity
- GAD-65 positivity
- 4.5%
Anti-islet cell autoantibodies
- Participants with anti-islet cell autoantibodies
- 0
Autoantibody positivity excluding 12 positive only for anti-insulin antibodies
- Autoantibody-positive
- 8.0%
- Median age of these
- 71 years
- Median BMI of these
- 31.8 kg/m²
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →